Survodutide Reconstitution Calculator

No. Survodutide is an investigational glucagon receptor/GLP-1 receptor dual agonist with no marketing approval reported in the current literature; reviews classify it as late-stage/emerging. Phase 3 efficacy data are published for obesity (SYNCHRONIZE-1, 76 weeks) and obesity with metabolic dysfunction-associated steatotic liver disease (SYNCHRONIZE-MASLD, 48 weeks). Outside clinical trials, access is only via unregulated supply channels (community context).

Injection only. Most human studies used once-weekly subcutaneous injection; phase 2 also tested twice-weekly dosing in type 2 diabetes. Phase 3 trials titrate to 3.6 mg or 6.0 mg weekly. As a peptide it has no meaningful oral bioavailability (mechanistic); no oral formulation appears in the published program. Orally available alternatives in the broader GLP-1 pipeline are separate molecules, not survodutide.

Phase 3 dosing: once-weekly subcutaneous, dose-adjusted up to 3.6 mg or 6.0 mg alongside lifestyle counseling; SYNCHRONIZE-CN instead used up to 4.8 mg weekly, so dose caps across phase 3 trials range from 4.8 to 6.0 mg depending on the trial. Phase 2 tested 0.6, 2.4, 3.6, and 4.8 mg weekly using a 20-week dose-escalation phase followed by 26 weeks of maintenance; weight loss was dose-dependent, from -6.2% (0.6 mg) to -14.9% (4.8 mg, planned-treatment analysis). Pooled meta-analysis identifies 2.4-4.8 mg/week as the optimal efficacy range. Because GI side effects are dose-dependent and concentrated during escalation, titration is driven by tolerability; slower escalation mitigates gastrointestinal AEs. Typical community practice mirrors this: start low (≈0.3-0.6 mg weekly) and step up every 2-4 weeks only if tolerated (community protocol).

In a 16-week head-to-head phase 2 trial in type 2 diabetes, survodutide reduced HbA1c by up to -1.71% vs -1.47% (semaglutide 1.0 mg) and body weight by up to -8.7% vs -5.3%. Against placebo in phase 3 (76 weeks), survodutide produced -12.2% (3.6 mg) and -13.0% (6.0 mg) body weight vs -5.4% placebo; about 72% achieved ≥5% weight loss vs 46.3% on placebo. No direct head-to-head RCT against tirzepatide exists in the published literature. Mechanistically, survodutide pairs GLP-1-driven appetite suppression with glucagon-driven energy expenditure and hepatic lipid handling, distinct from GLP-1 mono-agonists. Like other GLP-1-based agents, weight loss includes some lean-mass loss; body-composition data indicate lean-loss proportions comparable to established agents.

The longest published exposure is 76 weeks (phase 3); phase 2 ran 46 weeks. No longer-term survodutide data are published. Obesity is managed as a chronic disease, and GLP-1-class therapies show weight regain after discontinuation, so maintenance-duration treatment is the expected model once approved (practitioner consensus).

The dominant adverse events are gastrointestinal (nausea, vomiting, diarrhea), mostly mild-to-moderate and concentrated in dose escalation: 80.9% (3.6 mg) and 89.7% (6.0 mg) vs 47.9% placebo in phase 3. Treatment discontinuation due to AEs is dose-dependent and higher than placebo. Heart rate increases to a similar extent as GLP-1 mono-agonists, while blood pressure and glycemia fall. Formal cardiovascular safety and efficacy outcomes are not yet established; the event-driven SYNCHRONIZE-CVOT (NCT06077864) outcomes trial is ongoing. No pregnancy or breastfeeding data exist (trial populations were adults 18-75 years; survodutide should be avoided during pregnancy and breastfeeding (practitioner consensus).

This is its strongest differentiator. In the phase 3 SYNCHRONIZE-MASLD trial (6.0 mg weekly, 48 weeks), 84.2% vs 24.3% (placebo) achieved ≥30% reduction in MRI-assessed liver fat, with body weight change of -12.2% vs -1.0%. The phase 2 trial improved liver histology in MASH with fibrosis, and a network meta-analysis ranked survodutide 6 mg/week first (SUCRA 92%) for NASH resolution without worsening fibrosis. Reviews attribute the additional hepatic benefit to the glucagon component acting directly in the liver.

No official storage data are published for this investigational product. Standard practice for injectable peptide preparations: refrigerate reconstituted product (2-8°C), store lyophilized vials refrigerated or frozen long-term, avoid repeated freeze-thaw of reconstituted solution, and transport in an insulated carrier with cooling packs (community protocol). Because no approved commercial formulation exists, handling guidance applies to research-grade supply only (community context).